(+/-)3-methyl-4-[4-[3-(pyridin-2-yl)amino-1-propyloxy]phenyl]butanoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (+/-)3-methyl-4-[4-[3-(pyridin-2-yl)amino-1-propyloxy]phenyl]butanoic acid
• 英文别名: 3-Methyl-4-(4-(3-(pyridin-2-ylamino)propoxy)phenyl)butanoic acid；3-methyl-4-[4-[3-(pyridin-2-ylamino)propoxy]phenyl]butanoic acid
• 化学式: C₁₉H₂₄N₂O₃
• 分子量: 328.411
• InChiKey: MNMNKSRAIMNXQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  24
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  71.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-[(3-hydroxy-1-propyl)amino]pyridine-N-oxide 在 palladium on activated charcoal sodium hydroxide 、 乙醇 、 三苯基膦 、 环己烯 、 偶氮二甲酸二乙酯 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 (+/-)3-methyl-4-[4-[3-(pyridin-2-yl)amino-1-propyloxy]phenyl]butanoic acid
  参考文献：
  名称：

  Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective αvβ3 inhibitor: Design, synthesis, and optimization

  摘要：

  The integrin alpha(v)beta(3) is expressed in a number of cell types and is thought to play a major role in several pathological conditions. Various small molecules that inhibit the integrin have been shown to suppress tumor growth and retinal angiogenesis. The tripeptide Arg-Gly-Asp (RGD), a common binding motif in several ligands that bind to alpha(v)beta(3), has been depeptidized and optimized in our efforts toward discovering a small molecule inhibitor. We recently disclosed the synthesis and biological activity of several small molecules that did not contain any peptide bond and mimic the tripeptide RGD. The phenethyl group in one of the lead compounds was successfully replaced with a cyclopropyl moiety. The new lead compound was optimized for potency, selectivity, and for its ADME properties. We describe herein the discovery, synthesis, and optimization of cyclopropyl containing analogs that are potent and selective inhibitors of alpha(v)beta(3). (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.03.020

文献信息

• Vitronectin Receptor Antagonists
  申请人：SmithKline Beecham Corporation

  公开号：US20020147334A1

  公开（公告）日：2002-10-10

  Compounds of the formula (1) are disclosed which are vitronectin receptor antagonists and are useful in the treatment of osteoporosis: 1

  公式（1）的化合物被披露为抗血浆粘附素受体的拮抗剂，并且在骨质疏松症的治疗中有用：1
• [EN] VITRONECTIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR DE LA VITRONECTINE
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：WO1999045927A1

  公开（公告）日：1999-09-16

  (EN) Pharmaceutically active compounds which inhibit the vitronectin receptor and are useful for the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporosis.(FR) La présente invention concerne des composés pharmaceutiquement actifs inhibiteurs du récepteur de la vitronectine. Ces composés conviennent pour le traitement de l'inflammation, du cancer, et de troubles cardio-vasculaires tels que l'athérosclérose et la resténose. Ces composés conviennent également pour le traitement de maladies où intervient une résorption osseuse, et notamment l'ostéoporose.

  (中文)具有药理活性的化合物，可抑制玻璃蛋白原受体，用于治疗炎症、癌症和心血管疾病，例如动脉粥样硬化和再狭窄，以及骨吸收是因素的疾病，例如骨质疏松症。
• EP1061921A4
  申请人：——

  公开号：EP1061921A4

  公开（公告）日：2005-03-30
• VITRONECTIN RECEPTOR ANTAGONISTS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1061921A1

  公开（公告）日：2000-12-27
• Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective αvβ3 inhibitor: Design, synthesis, and optimization
  作者：Srinivasan R. Nagarajan、Hwang-Fun Lu、Alan F. Gasiecki、Ish K. Khanna、Mihir D. Parikh、Bipinchandra N. Desai、Thomas E. Rogers、Michael Clare、Barbara B. Chen、Mark A. Russell、Jeffery L. Keene、Tiffany Duffin、V. Wayne Engleman、Mary B. Finn、Sandra K. Freeman、Jon A. Klover、G. Alan Nickols、Maureen A. Nickols、Kristen E. Shannon、Christina A. Steininger、William F. Westlin、Marisa M. Westlin、Melanie L. Williams

  DOI：10.1016/j.bmc.2007.03.020

  日期：2007.5

  The integrin alpha(v)beta(3) is expressed in a number of cell types and is thought to play a major role in several pathological conditions. Various small molecules that inhibit the integrin have been shown to suppress tumor growth and retinal angiogenesis. The tripeptide Arg-Gly-Asp (RGD), a common binding motif in several ligands that bind to alpha(v)beta(3), has been depeptidized and optimized in our efforts toward discovering a small molecule inhibitor. We recently disclosed the synthesis and biological activity of several small molecules that did not contain any peptide bond and mimic the tripeptide RGD. The phenethyl group in one of the lead compounds was successfully replaced with a cyclopropyl moiety. The new lead compound was optimized for potency, selectivity, and for its ADME properties. We describe herein the discovery, synthesis, and optimization of cyclopropyl containing analogs that are potent and selective inhibitors of alpha(v)beta(3). (c) 2007 Elsevier Ltd. All rights reserved.